Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co and keeping the price target at $1,100.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mohit Bansal has given his Buy rating due to a combination of factors including Eli Lilly & Co’s strong quarterly performance and promising developments in its product portfolio. The company’s recent earnings exceeded expectations, and the upward revision in guidance for 2026 provides reassurance about its future financial outlook. This positive momentum is further supported by the robust growth of tirzepatide, which has become a leading product in the type 2 diabetes GLP-1 market.
Additionally, the expansion of manufacturing capacity is expected to sustain this growth trajectory. Despite some challenges, such as the CVS formulary change affecting Zepbound prescriptions, the overall growth prospects remain strong. The rapid expansion in the cash pay segment and the potential for increased vial sales also contribute to the positive outlook. These elements collectively underpin Bansal’s confidence in Eli Lilly’s ability to capitalize on opportunities in the obesity market, justifying the Buy rating.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $960.00 price target.
Based on the recent corporate insider activity of 120 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LLY in relation to earlier this year.